图书简介
Anticancer Agents: Frontiers in Cancer Chemotherapy describes cutting-edge approaches in the development of anticancer agents for chemotherapy.
Preface; 1: E. A. Sausville, J. I. Johnson, C. M. Cragg, and S. Decker: Cancer Drug Discovery and Development: New Paradigms for a New Millennium; 2: George R. Pettit: Evolutionary Biosynthesis of Anticancer Drugs; 3: John F. Kadow, Thomas Altstadt, Shu-Hui Chen, Pierre Dextraze Karen Du, Craig Fairchild, Jerzy Golik, Steven Hansel, Kathy A. Johnston, Robert A. Kramer, David R. Langley, Frank Lee, Byron Long, Harold Mastalerz, Carl Ouellet, Robert Perrone, William C. Rose, Paul Scola, Gene Schultz, Andrew Staab, Quifen May Xue, Michael Walker, Jen-Mei Wei, Mark Wittman, J. J. Kim Wright, Mary Zoeckler, and Dolatrai M. Yvas: Some Recent Developments in the Synthesis and SAR of Novel Taxanes; 4: Iwao Ojima, Scott D. Kuduk, Subrata Chakravarty, Songnian Lin, Tao Wang, Xudong Geng, Michael L. Miller, Pierre-Yves Bounaud, Young Hoon Park, Cuhung-Ming Sun, John C. Slater, Tadashi Inoue, Christopher P. Borella, John J. Walsh, Ralph J. Bernacki, Paula Pera, Jean Veith, Ezio Bombzrdelli, Antonella Riva, Srinivasa Rao, Hifeng He, George A. Orr, Susan B. Horwitz, Samuel J. Danishefsky, Giovanni Scambia, and Cristiano Ferlini: New Generation Taxoids and Hybrids of Microtube-Stabilizing Anticancer Agents; 5: Susan Band Horwitz, Laura A. Martello, Chia-Ping Y. Yang, Amos B. Smith, III, and Hayley M. McDaid: Discodermolide and Taxol: A Synergistic Drug Combination in Human Carcinoma Cell Lines; 6: Gregory D. Vite, Robert M. Borzilleri, Soong-Hoon Kim, Alicia Regueiro-Ren, W. Griffith Humphreys, and Francis Y. F. Lee: Highly Efficient Semisynthesis of Biologically Active Epothilone Derivatives; 7: Karl-Heinz Altmann, Marcel J. J. Blommers, Giorgio Caravatti, Andreas Florsheimer, Kyriacos C. Nicolaou, Terrence O’Reilly, Alfred Schmidt, Dieter Schinzer, and Markus Wartmann: Synthetic and Semisynthetic Analogs of Epothilones: Chemistry and Biological Activity; 8: Ulrich Klar, Werner Skuballa, Bernd Buchmann, Wolfgang Schwede, Thomas Bunte, Jens Hoffmann, and Rosemarie B. Lichtner: Synthesis and Biological Activity of Epothilones; 9: Nicolas Winssinger and K. C. Nicolaou: Epothelones and Sarcodictyins: From Combinatorial to Designed Analogs; 10: Chuan Shih, Rima S. Al-Awar, Andrew H. Fray, Michael J. Martinelli, Eric D. Moher, Bryan H. Norman, Vinod F. Patel, Richard M. Schultz, John E. Toth, David L. Varie, Thomas H. Corbett, and Richard E. Moore: Synthesis and Structure-Activity Relationship Studies of Cryptophycins: A Novel Class of Potent Antimitotic Tumor Depsipeptides; 11: J. B. Gibbs, N. J. Anthony, I. Bell, C. A. Buser, J. P. Davide, S. J. deSolms, C. Dinsmore, S. L. Graham, G. D. Hartman, D. C. Heimbrook, H. Huber, K. S. Koblan, N. E. Kohl, R. B. Lobell, and T. M. Williams: Farnesyltransferase Inhibitors as Potential Anticancer Agents; 12: John T. Hunt: Farnesyltransferase Inhibitors: From Squalene Synthase Inhibitors to the Clinical Agent BMS-214662; 13: A. G. Taveras, F. G. Njoroge, R. J. Doll, J. Kelly, S. Remiszewski, A. K. Mallams, C. S. Alvarez, J. del Rosario, R. R. Rossman, B. Vibulbhan, P. Pinto, J. Deskus, M. Connolly, J. Wang, J. Desai, R. Wolin, A. Afonso, A. B. Cooper, D. F. Rane, Y.-T. Liu, C. J. Aki, J. Chao, C. Strickland, P. Weber, M. Liu, M. S. Bryant, A. A. Nomeir, R. Patton, L. Wang, L. James, D. Carr, P. Kirschmeier, W. R. Bishop, V. Girijavallabhan, and A. K. Ganguly: Inhibiting Farnesyl Protein Transferase with Sch-66336: Potentially a Selective Non-Cytotoxic herapy for Human Cancer; 14: G. Caravatti, J. Bruggen, E. Buchdunger, R. Cozens, P. Furet, N. Lydon, T. O’Reilly, and P. Traxler: Pyrrolo[2,3- d]pyrimidine and Pyrazolo[3,4- d]pyrimidine Derivatives as Selective Inhibitors of the EGF Receptor Tyrosine Kinase; 15: Jurg Zimmermann, Pascal Furet, and Elisabeth Buchdunger: STI571: A New Treatment Modality for CML; 16: Andy Baxter and John Montana: The Discovery and Development of Second-Generation Matrix Metalloproteinase Inhibitors for the Treatment of Cancer; 17: Pascal Furet and Paul W. Manley: Prospects for Anti-Angiogenic Therapies Based upon VEGF Inhibition; 18: Jennifer R. Allen and Samuel J. Danishefsky: Carbohydrate-Based Tumor Antigens as Anti-Tumor Vaccine Agents; 19: Walter A. Blattler and Ravi V. J. Chari: Drugs to Enhance the Therapeutic Potency of Anti-Cancer Antibodies; Author Index
Trade Policy 买家须知
- 关于产品:
- ● 正版保障:本网站隶属于中国国际图书贸易集团公司,确保所有图书都是100%正版。
- ● 环保纸张:进口图书大多使用的都是环保轻型张,颜色偏黄,重量比较轻。
- ● 毛边版:即书翻页的地方,故意做成了参差不齐的样子,一般为精装版,更具收藏价值。
关于退换货:
- 由于预订产品的特殊性,采购订单正式发订后,买方不得无故取消全部或部分产品的订购。
- 由于进口图书的特殊性,发生以下情况的,请直接拒收货物,由快递返回:
- ● 外包装破损/发错货/少发货/图书外观破损/图书配件不全(例如:光盘等)
并请在工作日通过电话400-008-1110联系我们。
- 签收后,如发生以下情况,请在签收后的5个工作日内联系客服办理退换货:
- ● 缺页/错页/错印/脱线
关于发货时间:
- 一般情况下:
- ●【现货】 下单后48小时内由北京(库房)发出快递。
- ●【预订】【预售】下单后国外发货,到货时间预计5-8周左右,店铺默认中通快递,如需顺丰快递邮费到付。
- ● 需要开具发票的客户,发货时间可能在上述基础上再延后1-2个工作日(紧急发票需求,请联系010-68433105/3213);
- ● 如遇其他特殊原因,对发货时间有影响的,我们会第一时间在网站公告,敬请留意。
关于到货时间:
- 由于进口图书入境入库后,都是委托第三方快递发货,所以我们只能保证在规定时间内发出,但无法为您保证确切的到货时间。
- ● 主要城市一般2-4天
- ● 偏远地区一般4-7天
关于接听咨询电话的时间:
- 010-68433105/3213正常接听咨询电话的时间为:周一至周五上午8:30~下午5:00,周六、日及法定节假日休息,将无法接听来电,敬请谅解。
- 其它时间您也可以通过邮件联系我们:customer@readgo.cn,工作日会优先处理。
关于快递:
- ● 已付款订单:主要由中通、宅急送负责派送,订单进度查询请拨打010-68433105/3213。
本书暂无推荐
本书暂无推荐